No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK said on Monday that the European Medicines Agency had accepted its submission to update the label for its Bexsero asset, allowing for a singledose booster in people aged 10 and over who were previously vaccinated in childhood.
GSK said that, if approved, the booster would enable those who received Bexsero as infants to take a single additional dose from age 10 onwards, a move company believes could help reduce the burden of invasive meningococcal disease in countries with established MenB infant programmes.
The FTSE 100-listed firm said the filing was backed by a Phase 3b, openlabel, multicentre study assessing immune responses in 10 to 20yearolds who had completed the primary Bexsero series in infancy. The data showed a single booster dose effectively restored immune protection. Full results will be presented at the 25th International Pathogenic Neisseria Conference in September.
As of 0815 BST, GSK shares were down 0.37% at 1,909.50p.
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.